AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2022 Earnings Conference Call February 21, 2023 5:00 PM ET

Company Participants

Tryn Stimart - Chief Legal and Compliance Officer

Carl Hansen - Chairman, Chief Executive Officer, and President

Andrew Booth - Chief Financial Officer

Conference Call Participants

Tiago Fauth - Credit Suisse

Andrea Tan - Goldman Sachs

Gary Nachman - BMO

Robyn Karnauskas - Truist

Gaurav Goparaju - Berenberg

Antonia Borovina - Bloom Burton

Operator

Good afternoon. And welcome to AbCellera's Full-Year 2022 Business Update Conference Call. My name is Daniel, and I will facilitate the audio portion of today's interactive broadcast. [Operator instructions] At this time, I would like to turn the call over to Tryn Stimart, AbCellera’s Chief Legal and Compliance Officer. Please proceed.

Tryn Stimart

Thank you. Good afternoon, and welcome to AbCellera's full-year and fourth quarter 2022 business update. We're pleased to have you with us today as we will discuss the results announced in our press release issued after the market closed today, which you can find on our investor relations website. With me on the call today are Dr. Carl Hansen, AbCellera's Chief Executive Officer and President; and Andrew Booth, AbCellera's Chief Financial Officer.

The webcast portion of this call contains a slide presentation that we will refer to during the call. If you are following along on the phone and wish to access the slide portion of this presentation, you may do so on the investor relations section of our website. For those of you who have accessed the streaming portion of the webcast, please be aware that there may be a delay and that you will not be able to post questions via the web.

This presentation may contain forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Act of 1995. Any forward-looking statements are based on management's current expectations and are subject to certain risks and uncertainties. Please review our SEC filings for risk factors that could impact our future performance. Our presentation and SEC filings are available on our investor relations website. Note that all dollars referred to during our call today are U.S. dollars.

Now, I am pleased to turn the call over to Dr. Carl Hansen.

Carl Hansen

Thanks Tryn. And thanks everyone for joining us today. It’s my pleasure to provide an update on our business and the strong progress we made in 2022. 2022 marked AbCellera’s 10th anniversary. And in the year, we hit a symbolic milestone [in starting] [ph] our 100th partnered antibody discovery program.